Switzerland· 29863024
Petinutin, Kapseln
A mesuximide product containing mesuximidum, registered in Switzerland by Pfizer AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 3 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Mesuximide is registered in 3 of 19 countries.
Countries holding a registration under ATC N03AD03 (mesuximide), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 1 of them publish a price we can compare per daily dose
Mesuximide · ATC N03AD03
3 / 19 countries
- Germany
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of mesuximide costs, country by country.
Normalised to the WHO defined daily dose (0.9 g), so markets compare like for like.
- Switzerland: $1.37 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Mesuximide · price per daily dose (0.9 g)
USD · FX 28 Sept 2026
- CH Switzerland$1.37
The record
At a glance
Swissmedic (Switzerland)- Active substance
- mesuximidum
- Manufacturer
- Pfizer AG
- Country
- Switzerland (CH)
- ATC code
- N03AD03
- ATC class
- Mesuximide
- Defined daily dose
- 0.9 g, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680298630245100 StkCHF 37.8
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
61 interactions on record for mesuximide.
Graded by severity as the source publishes them — 61 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Mesuximide · interactions on record
61 records
- 61 moderate
Most severe, free to view
- MetoclopramideA03FA01moderate
- ThiethylperazinA04AB03moderate
- DiphenhydraminA04AB05moderate
- DronabinolA04AD10moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Mesuximide in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomCelontin 300mg KapsealsWarner-Pd
- United StatesCelontinParke-Davis Div of Pfizer Inc
- GermanyPetinutinPfizer Pharma Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Germany · Petinutin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e1267727-defd-4209-9b2a-d9a350d43692 GET /v1/drugs/e1267727-defd-4209-9b2a-d9a350d43692?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "mesuximidum 300 mg",
"valid_from": "1984-03-15",
"limitations": null,
"galenic_form": "Kaps 300 mg",
"therapeutic_area": null,
"sl_inclusion_date": "1984-03-15",
"self_retention_pct": 10
}See everything about mesuximide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.